Extranodal nasal NK/T cell lymphoma

This early-stage trial tests a new type of immune cell therapy (called universal CAR T cells) for people with certain blood cancers, including T-cell leukemia and lymphoma. The therapy targets a protein called CD7 found on cancer cells. The study will check if the treatment is sa…

This study tests a new type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CD7. It includes people with several blood cancers, such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia. The goal is…

This trial is testing a personalized approach for people with early-stage extranodal NK/T-cell lymphoma, a rare cancer of the immune system. All participants receive two cycles of induction chemotherapy (GELAD), then doctors check how well the tumor responded using a PET/CT scan …

This study tests two drugs, adebrelimab and SHR2554, together in about 40 adults whose T-cell lymphoma has come back or not responded to treatment. The goal is to find a safe dose and see if the combination can shrink tumors. Participants must have certain types of T-cell lymphom…

This study tests whether adding the drug sugemalimab to standard chemotherapy can help adults with a rare type of blood cancer (NK/T-cell lymphoma) that has returned or stopped responding to previous treatment. About 150 participants will receive either the new combination or a p…

This study tests a combination of three drugs (sintilimab, pegaspargase, and selinexor) followed by radiation in 47 people with newly diagnosed stage I/II extranodal NK/T-cell lymphoma, a rare blood cancer. The goal is to see how many patients achieve complete remission after tre…

This study tests whether adding the drug selinexor to a lower dose of radiation can treat early-stage NK/T-cell lymphoma just as well as standard high-dose radiation, but with fewer side effects. About 34 people who have not had prior treatment will receive chemotherapy first, th…

This study is testing a combination of three drugs—sintilimab, chidamide, and azacitidine—as a first treatment for people with early-stage extranodal NK/T-cell lymphoma, a rare blood cancer. About 30 participants will receive the drugs, and their response will guide further treat…

This phase 2 trial tests a combination of three drugs—golidocitinib, pegaspargase, and an immunotherapy—as a first treatment for advanced NK T-cell lymphoma, a rare and aggressive cancer. The study will enroll 40 people who have not had prior therapy. The goal is to see if this c…

This study tests whether adding the drug golidocitinib to standard chemotherapy and immunotherapy works better than the standard treatment alone for people with advanced NK/T-cell lymphoma, a rare blood cancer. About 40 adults will be randomly assigned to one of two groups. The m…

This study will develop an artificial intelligence model to predict how well patients with a rare type of lymphoma (NK/T-cell) respond to their first chemotherapy. Researchers will collect medical images and tissue samples from 100 participants to train the AI. The goal is to hel…